Emapalumab by Swedish Orphan Biovitrum for Systemic-Onset Juvenile Idiopathic Arthritis …
According to GlobalData, Phase III drugs for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) have an 89% phase transition success rate ( ... According to GlobalData, Phase III drugs for Systemic-Onset…